Loading...
Please wait, while we are loading the content...
Similar Documents
Latrepirdine, a potential novel treatment for Alzheimer’s disease and Huntington’s chorea
| Content Provider | PubMed Central |
|---|---|
| Author | Sabbagh, Marwan N. Shill, Holly A. |
| Abstract | Latrepirdine (Dimebon) is a novel compound currently under development by Medivation Inc and Pfizer Inc for the treatment of Alzheimer’s disease and Huntington’s chorea. Originally developed and marketed as an antihistamine in Russia, it has potential for the treatment of neurodegenerative diseases. Early research suggested that the mechanism of action is centered on AChE inhibition and NMDA antagonism. Newer research casts some doubt regarding these early findings and other mechanisms of action have been proposed and investigated. In phase II clinical trials, latrepirdine demonstrated clinically relevant improvements in patients with Alzheimer’s disease and Huntington’s chorea. At the time of publication, phase III clinical trials had been initiated. Given the robustness of the phase II clinical data, latrepirdine has a high likelihood of success in phase III trials and in subsequently being granted regulatory approval. |
| Starting Page | 80 |
| File Format | |
| ISSN | 20403429 |
| e-ISSN | 20403429 |
| Journal | Current Opinion in Investigational Drugs |
| Issue Number | 1 |
| Volume Number | 11 |
| Language | English |
| Publisher Date | 2010-01-01 |
| Access Restriction | Open |
| Subject Keyword | Research in Higher Education |
| Content Type | Text |
| Resource Type | Article |
| Subject | Drug Discovery Pharmacology |
